William Blair analyst Myles Minter downgraded Alector (ALEC) to Market Perform from Outperform without a price target after the Phase III miss and discontinuation of the latozinemab program. The firm needs to see clinical data for Alector’s platform to evaluate its other programs.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector downgraded to Neutral from Overweight at Cantor Fitzgerald
- Alector downgraded to Neutral from Outperform at Mizuho
- Alector downgraded to Hold from Buy at TD Cowen
- Closing Bell Movers: Intuitive Surgical, Capital One jump after earnings
- Alector discontinues extension portion of INFRONT-3 trial